EcoR1 Capital’s Adicet Bio ACET Stock Holding History

EcoR1 Capital’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-222,544	Closed	-$20.5M	–	54
2023 Q1	$20.5M	Hold	222,544	–	–	0.66%	28
2022 Q4	$31.8M	Buy	+222,544	New	+$55.5M	0.97%	18

Other funds holding ACET

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

EcoR1 Capital's ACET Position: Q2 2023 in Review

EcoR1 Capital sold out of Adicet Bio (ACET) in Q2 2023, closing a stake of 222,544 shares — an estimated $20.5M sold.

EcoR1 Capital first reported a position in ACET in Q4 2022 and held it in 2 quarters. The position peaked at $31.8M in Q4 2022. 94 funds tracked by Wall St. Rank hold ACET as of Q2 2023.

EcoR1 Capital reported no remaining Adicet Bio position as of Q2 2023 after selling out during the quarter.
EcoR1 Capital sold 222,544 Adicet Bio shares in Q2 2023, an estimated $20.5M.
EcoR1 Capital first reported a position in Adicet Bio in Q4 2022 and held it in 2 quarters.
EcoR1 Capital's Adicet Bio position peaked at $31.8M in Q4 2022.
94 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2023.

Based on EcoR1 Capital's 13F filing for Q2 2023, filed 14 Aug 2023.